Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT02767804 trial: what clinicians have said so far
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- NCT02767804 ↗
- Active, not recruiting
- Xcovery Holdings, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT02767804 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02767804 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- X-396 (ensartinib); crizotinib
- Arms
- X-396 (ensartinib) · Experimental
- crizotinib · Active comparator
- Enrollment
- 290
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- Xcovery Holdings, Inc.
- Start
- Jun 2016
- Primary completion
- Dec 30, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT02767804 · updated Oct 14, 2025
Publications
linked from the registry- Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, Whisenant JG, Zhou Y, Oertel V, Harrow K, Liang C, Mao L, Selvaggi G, Wu YL. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021 Nov 1;7(11):1617-1625. doi: 10.1001/jamaoncol.2021.3523. PubMed 34473194